Align Technology, has signed a non-exclusive agreement with digital prosthetic solutions provider Zfx to expand the restorative and laboratory marketplace for its iTero Element® intraoral scanners.
Pursuant to the agreement, Zfx will sell Align Technology's iTero scanners among its network of laboratories, milling centres, and dental professionals in major European, Asian, and African markets.
The partnership enables practitioners and dental laboratories to access high-quality iTero intraoral scanners along with the Zfx digital restorative platform, thus enabling them to produce high-quality dental prosthetics.
SQI Diagnostics (SQI) has signed an agreement with a predictive diagnostic medicine company based in Irvine, Caliornia.
Under the agreement, SQI will upgrade the Irvine-based company’s multi-biomarker test into an SQI-based multiplex test and will automate it on SQI’s sqidlite system. The test is a first-of-its-kind to detect heart attack risk factors using a blood sample.
The kits will be developed in SQI’s state-of-the-art facility in Toronto and sold along with the SQI automation systems to the Irvine-based company’s global customer base, which includes cardiologists, hospitals, and reference laboratories.
Integra LifeSciences has signed an exclusive distribution agreement with Dr. Reddy's Laboratories for the marketing and distribution of its innovative regenerative technology solutions to neurosurgeons and patients in India.
Pursuant to the agreement, Dr Reddy's Laboratories will commercialise Integra LifeSciences' DuraGen Plus® and Suturable DuraGen® dural regeneration matrices in India, building its presence in the regenerative technologies segment.
The DuraGen line of products offers duraplasty solutions for the repair of the dura mater, a thick membrane that surrounds the brain and spinal cord.
Owlstone Medical has received an investment from Aviva Ventures bringing its total funding to $23.5m since its spin-out in 2016.
The funds will be used by Owlstone for test adoption and commercialisation of its Breath Biopsy platform, which uses field asymmetric ion mobility spectrometry (FAIMS) technology to measure volatile organic compound (VOC) metabolites in patient’s breath that are specific to disease. The method enables non-invasive diagnosis of diseases at a very early stage.